Paladin Advisory Group’s Edwards Lifesciences EW Stock Holding History

Paladin Advisory Group’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,356	Closed	-$101K	–	337
2022 Q4	$101K	Hold	1,356	–	–	0.09%	123
2022 Q3	$112K	Hold	1,356	–	–	0.1%	117
2022 Q2	$128K	Buy	+1,356	New	+$140K	0.11%	112
2022 Q1	–	Sell	-1,356	Closed	-$175K	–	349
2021 Q4	$175K	Buy	+1,356	New	+$158K	0.14%	104

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Paladin Advisory Group's EW Position: Q1 2026 in Review

Paladin Advisory Group held its Edwards Lifesciences (EW) position steady in Q1 2026 at 653 shares worth $52.3K. The position accounts for 0.04% of the portfolio, ranked #146.

Paladin Advisory Group first reported a position in EW in Q1 2022 and has held it in 14 quarters since. The position peaked at $166K in Q1 2022. 1,284 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Paladin Advisory Group held 653 shares of Edwards Lifesciences worth $52.3K as of Q1 2026.
Paladin Advisory Group left its Edwards Lifesciences share count unchanged in Q1 2026.
Edwards Lifesciences made up 0.04% of Paladin Advisory Group's portfolio in Q1 2026, its #146 holding.
Paladin Advisory Group first reported a position in Edwards Lifesciences in Q1 2022 and has held it in 14 quarters since.
Paladin Advisory Group's Edwards Lifesciences position peaked at $166K in Q1 2022.
1,284 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Paladin Advisory Group's 13F filing for Q1 2026, filed 30 Apr 2026.